Oxytocin — Endogenous neurohormone (cyclic nonapeptide). 9-residue sequence shown as a side-chain class strip (1 aromatic, 4 polar, 4 nonpolar). Molecular weight 1007.2 g/mol.
Cognitive & Nootropic

Oxytocin

Endogenous neurohormone (cyclic nonapeptide)

A naturally occurring nonapeptide studied extensively in social-behavior and neuropeptide research.

Also referenced as: OXT

9 aat½ Approximately a few minutes in circulation
For research and educational purposes only. This page is a factual research reference, not medical advice. Any dosing figures shown are amounts reported in the research literature, provided for educational context — not instructions or recommendations for human use.

Overview

Oxytocin is a naturally occurring nonapeptide hormone synthesized in the hypothalamus and released from the posterior pituitary. It was among the first peptide hormones to be sequenced and chemically synthesized (work by Vincent du Vigneaud).

At a glance

ClassEndogenous neurohormone (cyclic nonapeptide)
CategoryCognitive & Nootropic
SequenceCys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly (disulfide-bridged, C-terminal amide)
Chain length9 amino acids
Molecular weight1007.2 g/mol
Half-lifeApproximately a few minutes in circulation
Typical formLyophilized powder
AliasesOXT
Use designationResearch / in-vitro only
Regulatory statusOxytocin is an FDA-approved drug in obstetric medicine and a natural human hormone; its use in social, cognitive, or psychiatric contexts is investigational and not approved. Educational content only, not medical advice.

What Oxytocin does

Oxytocin is an endogenous nine-amino-acid neuropeptide and hormone, synthesized in the hypothalamus, best known peripherally for uterine contraction and milk let-down. In the brain, what it does in research is modulate social and emotional processing: it has been observed to increase trust, social approach, and reading of social cues, and to reduce social anxiety and fear responses. These central actions are the focus of cognitive and psychiatric research (autism, social anxiety disorder, PTSD).

Mechanistically, oxytocin acts on oxytocin receptors concentrated in social-emotional circuitry, especially the amygdala and extended amygdala (central nucleus and bed nucleus of the stria terminalis). In human neuroimaging it reduces amygdala reactivity to threatening stimuli and alters amygdala functional connectivity, an effect that helps explain its anxiolytic and pro-social profile. At the circuit level it can inhibit centromedial amygdala output by exciting local GABAergic interneurons, thereby suppressing fear signaling, and its stress- and threat-related effects are critically dependent on interaction with the serotonin system. Notably, its amygdala effects are sex-dependent (inhibitory in males, sometimes enhancing in females).

The evidence is a large human literature but with important limitations. Intranasal oxytocin studies show real acute effects on social cognition and amygdala activity, yet results are heterogeneous, effect sizes are modest and context-dependent, brain penetration after intranasal dosing is debated, and large clinical trials (e.g., in autism) have often failed to show robust benefit.

Effects reported in research

  • Reduced amygdala reactivity to threatening or fearful stimuli in human neuroimaging (human).
  • Increased trust, generosity, and social-approach behavior in behavioral-economics and social tasks (human).
  • Improved recognition of facial emotion and social cues in some studies (human).
  • Anxiolytic effects during social threat, especially in males, with sex-dependent amygdala modulation (human).
  • Altered amygdala functional connectivity in generalized social anxiety disorder (human).
  • Inhibition of central-amygdala fear output via excitation of local GABAergic interneurons (animal).
  • Threat- and stress-related effects shown to depend critically on the serotonin system (human/animal).
  • Peripheral physiological actions (uterine contraction, milk let-down) via the same receptor (established human physiology).

Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.

Mechanism of action

Oxytocin acts through the oxytocin receptor, a G-protein-coupled receptor, mediating uterine contraction and milk let-down in its classical endocrine roles. In the central nervous system it is studied as a neuromodulator involved in social bonding, trust, and stress regulation. Its cyclic structure includes an intramolecular disulfide bond and a C-terminal amide.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which Oxytocin appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Labor induction and postpartum hemorrhage (established medical use)Lactation/milk ejectionSocial bonding and affiliative behaviorAutism spectrum and social cognition (investigational)Anxiety and stress regulation (investigational)

Key characteristics

  • A natural human hormone as well as an approved obstetric medication
  • Structurally a cyclic nonapeptide with a disulfide bridge
  • Closely related in structure to vasopressin, differing by two amino acids
  • Widely studied as a CNS neuromodulator of social behavior
  • Approved obstetric uses are distinct from investigational behavioral/cognitive uses

Reported research dosing reference only

Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Oxytocin is a research compound.

Human behavioral studies most commonly use a single intranasal dose around 24 IU (roughly 24-40 IU range), with 1 IU equal to about 2 mcg of peptide. These are reference figures for research context only, not human dosing guidance.

  • Behavioral research: ~24 IU single intranasal dose (commonly 24-40 IU)
  • Subcutaneous/IV comparison protocols: ~2-5 IU for comparable plasma levels
Reported frequencyTypically a single acute dose timed before a behavioral task in social-cognition studies
ReconstitutionAvailable both as a solution and, for research peptide vials, as a lyophilized powder reconstituted with bacteriostatic water

IV plasma half-life ~3-5 minutes; poor BBB penetration from the periphery motivates intranasal use

How it compares

Oxytocin is a naturally occurring, FDA-approved hormone, unlike the synthetic research peptides in this class; its behavioral/cognitive applications remain investigational.

Commonly studied alongside

Compounds frequently researched together with Oxytocin in the literature. Cross-referenced for research context — not a usage or combination recommendation.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for Oxytocin, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

  • Avoid repeated freeze-thaw cycles
  • Verify supplier lot and Certificate of Analysis
  • Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

Oxytocin sits in the Cognitive & Nootropic area of the PeptiDex library.

Research Supplier Listing

Where researchers source Oxytocin

For researchers studying Oxytocin, third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.

Explore Research Suppliers →

PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.

Frequently asked questions

What is oxytocin as a research peptide?

Oxytocin is a nine-amino-acid cyclic neuropeptide and hormone, with an intramolecular disulfide bridge between its two cysteine residues. In behavioral research it is studied for its roles in social bonding, trust, and stress modulation, and it is also a well-characterized endogenous hormone.

Why is intranasal oxytocin used in behavioral research?

Peripherally administered oxytocin crosses the blood-brain barrier poorly, so intranasal delivery is the standard route in social-cognition studies to promote nose-to-brain access. Its short plasma half-life of only a few minutes makes route of administration an important design factor.

How is oxytocin dosed in human research studies?

The most common intranasal research dose is 24 IU, often delivered as multiple sprays across both nostrils, with a typical range around 24-40 IU. One IU corresponds to roughly two micrograms of pure peptide, which is a useful conversion when interpreting protocols.

What does oxytocin's short half-life imply for study design?

With an intravenous plasma half-life of only about 3-5 minutes, oxytocin's acute effects are time-limited, and intranasal delivery is thought to extend the relevant behavioral window to roughly 45-60 minutes. Studies therefore commonly time behavioral tasks to a defined post-dose window.

Is oxytocin an approved drug?

Oxytocin is an approved medicine in obstetric contexts (for example labor induction and postpartum use) delivered by injection. The intranasal behavioral-research use studied in social cognition is not an approved indication and is investigational.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

Primary literature indexed in PubMed for Oxytocin. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).

  1. The Oxytocin Receptor: From Intracellular Signaling to Behavior Physiol Rev, 2018. PubMed 29897293
  2. Is Oxytocin "Nature's Medicine"? Pharmacol Rev, 2020. PubMed 32912963

Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.

Related compounds in Cognitive & Nootropic

Further reading